52\textsuperscript{nd} Malaysia-Singapore Congress of Medicine

incorporating

- Annual Scientific Meeting 2018 of the College of Physicians, AMM
- Annual Scientific Congress of the Malaysian Oncological Society (ASCOMOS) 2018

27\textsuperscript{th} - 29\textsuperscript{th} July 2018
Royale Chulan Kuala Lumpur, Malaysia

Battling Cancer - What Is Your Role?

SOUVENIR PROGRAMME

mscm.acadmed.my
Moments like this are too important to miss.

Dissolves breakthrough cancer pain fast

*Significant pain relief from 10 minutes post-dose (p = 0.006 vs. placebo)

Abbreviated Prescribing Information
Abstral 100, 200 and 400 micrograms Sublingual Tablets (fentanyl [as citrate]). Abbreviated Prescribing Information, please refer to Product Information. Administration: Sublingual tablets containing 100, 200 and 400µg of fentanyl are administered as an alternative to parenteral and oral routes of administration. Oral fentanyl is not recommended for the treatment of cancer pain. Oral fentanyl tablets are contraindicated in chronic pain management. Oral fentanyl tablets are contraindicated in patients with a history of drug addiction or alcoholism.

Instructions:
Management of breakthrough pain (BTP): A sublingual tablet of Abstral is administered to the patient when breakthrough pain occurs. The patient is instructed to place the tablet under the tongue and allow it to disintegrate. The tablet should be taken until the pain is relieved. If pain returns before the tablet is fully disintegrated, a second tablet should be administered. If pain occurs at a time when the patient is unable to take a tablet, another tablet of Abstral or an equivalent opioid should be administered. In the management of breakthrough pain with Abstral tablets, patients should receive additional opioids that are appropriate for their condition. Patients should be monitored for adverse effects, including respiratory depression, sedation, and delay in awakening.

Contraindications:
Patients with a history of drug addiction or alcoholism are not recommended for the treatment of breakthrough pain with Abstral tablets. Patients with a history of drug addiction or alcoholism should be monitored for adverse effects, including respiratory depression, sedation, and delay in awakening. In the management of breakthrough pain with Abstral tablets, patients should receive additional opioids that are appropriate for their condition. Patients should be monitored for adverse effects, including respiratory depression, sedation, and delay in awakening.

Warnings and Precautions:
Patients should be monitored for adverse effects, including respiratory depression, sedation, and delay in awakening. In the management of breakthrough pain with Abstral tablets, patients should receive additional opioids that are appropriate for their condition. Patients should be monitored for adverse effects, including respiratory depression, sedation, and delay in awakening.

Additional information:
Abstral tablets should be administered to the patient when breakthrough pain occurs. The tablet should be placed under the tongue and allowed to disintegrate. The tablet should be taken until the pain is relieved. If pain returns before the tablet is fully disintegrated, a second tablet should be administered. If pain occurs at a time when the patient is unable to take a tablet, another tablet of Abstral or an equivalent opioid should be administered. In the management of breakthrough pain with Abstral tablets, patients should receive additional opioids that are appropriate for their condition. Patients should be monitored for adverse effects, including respiratory depression, sedation, and delay in awakening.

MENARINI
A. Menarini Singapore Pte Ltd. (9942477)
Tel: (+603) 7985 7000 / (+603) 7985 7100 fax: (+603) 7955 5330 www.menarinipacific.com
KEYTRUDA® (pembrolizumab) is indicated for the first-line treatment of patients with metastatic non–small cell lung carcinoma (NSCLC) whose tumors express PD-L1 with a ≥ 50% tumor proportion score (TPS) as determined by a validated test, with no EGFR or ALK genomic tumor aberrations.

KEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic NSCLC whose tumors express PD-L1 with a ≥ 1% TPS as determined by a validated test and who have disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on approved therapy for these aberrations prior to receiving KEYTRUDA.

PD-L1 = programmed death ligand 1; EGFR = epidermal growth factor receptor; ALK = anaplastic lymphoma kinase.

SELECTED SAFETY INFORMATION

Contraindications and Boxed Warnings: Hypersensitivity to pembrolizumab or any of the inactive ingredients. Precautions/Warnings: Immune-mediated adverse reactions, including pneumonitis, colitis, hepatitis, nephritis, hypophysitis, type 1 diabetes mellitus, diabetic ketoacidosis, thyroid disorders, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), uveitis, myositis, Guillain-Barré syndrome, pancreatitis, solid organ transplant rejection, and infusion-related reactions, occurred in patients receiving KEYTRUDA. Immune-related adverse reactions have also occurred after the last dose of KEYTRUDA. Immune-mediated adverse reactions affecting more than one body system can occur simultaneously. For more information and management of immune-related adverse reactions and infusion-related reactions, see full prescribing information of KEYTRUDA. Adverse Events: Most common adverse reactions (reported in ≥10% of patients): melanoma included arthralgia, back pain, cough, vitiligo, pruritus, abdominal pain, rash, hypotension, NSCLC included cough, rash, pruritus, HNSCC similar to those occurring in patients with melanoma or NSCLC. For detailed adverse events, please consult the full prescribing information.

Drug Interactions: No metabolic drug-drug interactions are expected. The use of systemic corticosteroids or immunosuppressants before starting KEYTRUDA should be avoided but can be used after starting KEYTRUDA to treat immune-mediated adverse reactions. Refer to the local full prescribing information of KEYTRUDA for more information.

Before prescribing KEYTRUDA®, please read the accompanying Prescribing Information.

For Healthcare Professionals only.

MERCK SHARP & DOHME (MALAYSIA) SDN. BHD.
B-22-1 & B-22-2, The Ascent Paradigm, No 1, Jalan SS 7/26A, Kelana Jaya, 47301 Petaling Jaya, Selangor Darul Ehsan, Malaysia
Tel: (603) 74991600 | Fax: (603) 74991700 | www.msd-malaysia.com
Copyright © 2018 Merck Sharp & Dohme (M) Sdn. Bhd., a subsidiary of Merck & Co., Inc, Kenilworth, NJ, USA. All rights reserved.
ONCO-1260142-0000 06/18
Contents

Messages
• Master, Academy of Medicine, Singapore & President of the Congress 5
• Master, Academy of Medicine of Malaysia 6
• President, Hong Kong Academy of Medicine 7
• Organising Chairperson & Co-Chairpersons, 52nd Malaysia-Singapore Congress of Medicine 8

Opening Ceremony Programme 9

Presidential Dinner and Jade Ribbon Gala Event Programme 10

Councils / Committees
• Academy of Medicine of Malaysia - Council 2017 - 2018 11
• Academy of Medicine, Singapore - Council 2018 - 2019 12
• Hong Kong Academy of Medicine - Council 2017 - 2018 13
• College of Physicians, Academy of Medicine of Malaysia - Council 2016 - 2018 14
• Malaysian Oncological Society - Council 2015 - 2018 14
• Committees 15 - 16

Invited Faculty 17

22nd Tun Dr Ismail Orator - Professor Dato’ Dr Khalid Abdul Kadir 18
Citation by Tan Sri Dato’ Dr Yahya Awang

Tun Dr Ismail Orations 19

4th T J Danaraj Orator - Professor Dr Victor Lim 20
Citation by Dato’ Dr Alex Mathews

Citations - Fellows of the Academy of Medicine of Malaysia 21 - 26

Programme Summary 27

Pre-Congress Workshops 28

Daily Programme
• 27th July 2018 (Friday) 29 - 30
• 28th July 2018 (Saturday) 31 - 32
• 29th July 2018 (Sunday) 33

Floor Plan & Trade Exhibition 34

Thank You / Acknowledgements 35

Poster Presentations 36 - 37
DYMM PADUKA SERI SULTAN PERAK DARUL RIDZUAN
SULTAN NAZRIN MUIZZUDDIN SHAH IBNI ALMARHUM
SULTAN AZLAN MUHIBBUDDIN SHAH
It gives me great pleasure to welcome all delegates to the 52nd Malaysia-Singapore Congress of Medicine incorporating the Annual Scientific Meeting 2018 of the College of Physicians and Annual Scientific Congress 2018 of the Malaysian Oncological Society. On behalf of the Council of the Academy of Medicine, Singapore, I congratulate the Academy of Medicine of Malaysia and the Organising Committee for putting up a good programme that stimulates both our clinical knowledge and scientific intellect.

With the rising global concern and increasing number of cancer cases diagnosed around the world, the theme for this year’s Congress, “Battling Cancer - What Is Your Role?”, couldn’t be more apt and relevant. We have an important role to play - individually or collectively - to reduce the global burden of cancer and there is an urgent need to mobilize our efforts in cancer prevention, early detection, care and support of the patients.

This annual scientific gathering in the Asia Pacific Region will provide the ideal platform for medical experts and healthcare practitioners from around the world to come together to share knowledge and information on the advances in the research, early diagnosis and treatment of cancer, while considering both global and regional aspects. It is only through an exchange of the widest variety of research that we can offer the best programme and benefits to our patients. Everyone has a part to play in the ongoing fight against cancer and we are all here with the ultimate purpose of learning how we can improve the services we provide to our patients who are battling with cancer.

In addition to this great learning and networking platform, do take the opportunity to renew old friendships, make new contacts and enjoy your stay in the vibrant and beautiful Kuala Lumpur.

I wish everyone a fruitful and enjoyable Congress.

Dr S R E Sayampanathan
Master, Academy of Medicine, Singapore & President of the Congress
It gives me immense pleasure to welcome you to the 52nd Malaysia-Singapore Congress of Medicine with the theme, “Battling Cancer - What Is Your Role?”, jointly organised by the Academy of Medicine of Malaysia (AMM), the College of Physicians, AMM, and the Malaysian Oncological Society. I would like to congratulate the Organising Committee for their tremendous efforts to bring this Congress to fruition and the Scientific Committee who has designed a thought-provoking programme which not only focuses on the state-of-the-art and current aspects of cancer management, but also includes substantial emphasis on a multidisciplinary approach which is vital to improving the quality of life of cancer patients.

The highlight of the social event is the Presidential Dinner and the Jade Ribbon Gala Event which is held in conjunction with WHO World Hepatitis Day on 28th July 2018. The Jade Ribbon Campaign is an international movement to help spread awareness of liver cancer which is the second-leading cause of cancer deaths worldwide and rising in importance as a global killer. The Jade Ribbon Gala Event aims to focus the spotlight on the AMM’s advocacy role and inspire everyone to take action in reducing the liver cancer burden.

I would like to wish all the participants a fruitful meeting and hope that you will have an enjoyable time while attending a memorable educational event.

Professor Dr Rosmawati Mohamed
Master
Academy of Medicine of Malaysia
On behalf of the Hong Kong Academy of Medicine, it gives me great pleasure to offer my sincerest congratulations to the Academy of Medicine of Malaysia on its 52nd Malaysia-Singapore Congress of Medicine.

For over half a century, this Congress has been serving as an excellent platform bringing together regional and international medical leaders and experts to deliberate on healthcare issues and exchange knowledge and experience. As a major conference in the Asia Pacific region, it has generated numerous successful collaboration outcomes between the two academies in Malaysia and Singapore.

With the theme “Battling Cancer - What Is Your Role?”, this Congress not only fosters exchanges among oncologists but also reminds us, as doctors, of our commitment to fight against diseases together with our patients. I believe all participants would gain insights into the importance of delivering multidisciplinary care for oncology patients. May I wish you a most fruitful conference!

Professor Lau Chak-sing
President
Hong Kong Academy of Medicine
It is a great pleasure and an honour to welcome you to our 52nd Malaysian-Singapore Congress of Medicine 2018 in Kuala Lumpur, Malaysia from 27th to 29th July 2018. This year, the conference is jointly organised by the Academy of Medicine of Malaysia, the Malaysian Oncological Society and the College of Physicians, AMM. In keeping with our theme, “Battling Cancer - What Is Your Role?”, we have prepared an exciting line-up of topics and activities that will highlight the need for collaboration and cooperation of individuals from a wide range of professional backgrounds in dealing with cancer.

Interest in cancer research, funding and care has grown tremendously over recent years in the Malaysian healthcare landscape. Whilst these are welcome developments, resources available to healthcare practitioners to provide the right diagnosis, the right treatment and the right management for cancer patients, seem inevitably inadequate. Community awareness on cancer screening requires continuous effort and community-based cancer care services need to be more widely available. The challenges of financial toxicities needed to be overcome. Moreover translational cancer research requires a deeper understanding and acceptance by society at large.

It is time for everyone to get a good grip and uphold their role in battling this vicious enemy. It may happen to any one of us whilst we wish to deny it; whereas for the survivors, it is all about rebirth and glory of a second chance.

It is worth mentioning that Kuala Lumpur is an exceptional location for the Congress to be held. It is renowned as one of the world’s most popular destinations for conventions, blending a unique mix of time-honoured traditions with a modern setting. We hope it offers plenty of networking opportunities to meet and interact with the leading scientists, researchers, friends and colleagues as well as sponsors and exhibitors.

We hope you will enjoy the orchestra of science, collegiality and culture, and take a little extra time to enjoy the spectacular and unique beauty of Kuala Lumpur, Malaysia.

Associate Professor Dr Bahariah Khalid
Chairperson
Organising Committee

Dr Matin Mellor
Co-Chairperson
Organising Committee

Professor Dr Roslina Abdul Manap
Co-Chairperson
Organising Committee
OPENING CEREMONY

Date: 27th July 2018 (Friday)
Venue: Tamingsari 1 & 2, Royale Chulan Kuala Lumpur

1500 Arrival of Guests and Delegates
1520 Guests and Delegates to be Seated
1530 Arrival of Duli Yang Maha Mulia Paduka Seri Sultan Perak Darul Ridzuan, Sultan Nazrin Muizzuddin Shah Ibni Almarhum Sultan Azlan Muhibbuddin Shah
1540 Academic Procession
1550 Address by Professor Dr Rosmawati Mohamed Master, Academy of Medicine of Malaysia
1600 Address by Professor Lau Chak-sing President, Hong Kong Academy of Medicine
1610 Address by Dr S R E Sayampanathan Master, Academy of Medicine, Singapore
1620 Declaration of the Opening of the Congress by Duli Yang Maha Mulia Paduka Seri Sultan Perak Darul Ridzuan, Sultan Nazrin Muizzuddin Shah Ibni Almarhum Sultan Azlan Muhibbuddin Shah
1625 Conferment of Fellowship on Presidents of Overseas Academies / Colleges / Organisations
1630 Conferment of Fellowship on Academicians
1640 Induction of New Members of the Academy of Medicine of Malaysia
1720 Citation on 22nd Tun Dr Ismail Orator by Tan Sri Dato’ Dr Yahya Awang
1730 22nd Tun Dr Ismail Oration: “Medical Research: A Matter of Life and Health” by Professor Dato’ Dr Khalid Abdul Kadir
1810 Academic Procession
1820 Welcome Reception
# PRESIDENTIAL DINNER AND JADE RIBBON GALA EVENT

**Date:** 28<sup>th</sup> July 2018 (Saturday)

**Venue:** Tamingsari 1 & 2, Royale Chulan Kuala Lumpur

1930  Registration and Arrival of VIPs and Guests

1945  Arrival of YBhg Datuk Dr Noor Hisham Abdullah
       Director-General of Health Malaysia

1950  Arrival of Guest of Honour
       YB Dr Lee Boon Chye
       Deputy Minister of Health Malaysia

2000  Welcome Speech by Professor Dr Rosmawati Mohamed
       Master, Academy of Medicine of Malaysia

2010  Speech by YB Dr Lee Boon Chye
       Deputy Minister of Health Malaysia

2020  Dinner Commences
       Entertainment

2040  Video of Activities of the Academy of Medicine of Malaysia and Its Colleges
       Cultural Performance

2050  Honouring Past Masters of the Academy of Medicine of Malaysia
       • Professor Dato’ Dr Khalid Abdul Kadir
       • Professor Dato’ Dr P Kandasami

2055  Lifetime Achievement Award of the College of Physicians,
       Academy of Medicine of Malaysia
       • Professor Dato’ Dr Khalid Abdul Kadir

2100  Exchange of Gifts
       Entertainment

2120  Jade Ribbon Gala Event

2200  End of Function

*Dress Code: Lounge Suit*
PRESIDENTS OF COLLEGES

Anaesthesiologists
- Dr Raveenthiran Rasiah

Dental Specialists
- Emeritus Professor Dato’ Dr Lian Chin Boon
- Dr Mahathar Ab Wahab

Emergency Physicians
- Dr Michael Samy

Obstetricians & Gynaecologists
- Dr Pall Singh

Ophthalmologists
- Professor Dr Thong Meow Keong

Paediatrics
- Emeritus Professor Dr Cheong Soon Keng

Pathologists
- Dr Letchuman Ramanathan

Physicians
- Professor Datuk Dr Lokman Hakim (until 20th April 2018)
- Dato’ Indera Dr Sha’ari bin Ngadiman (from 20th April 2018)

Public Health Medicine
- Dr Amir Fuad

Radiology
- Professor Dato’ Dr Hanafiah Harunarashid

Surgeons
- Dato’ Dr Hanafiah Harunarashid

Standing front (left to right)
- Dr Amir Fuad, Dr Raveenthiran Rasiah, Professor Dr Roslina Abdul Manap, Professor Dato’ Dr P Kandasami, Dr Steven Chow Kim Weng, Professor Dr Rosmawati Mohamed, Dr Goh Kim Yen, Professor Dato’ Dr Adeeba Kamarulzaman, Associate Professor Dr Andrew Tan Khian Khoon

Standing back (left to right)
- Dr Pall Singh, Professor Dato’ Dr Hanafiah Harunarashid, Emeritus Professor Dr Cheong Soon Keng, Dr Mahathar Ab Wahab, Professor Dr Thong Meow Keong, Dr Michael Samy, Dr Letchuman Ramanathan, Dr Milton Lum Siew Wah, Emeritus Professor Dato’ Dr Lian Chin Boon
ACADEMY OF MEDICINE, SINGAPORE
COUNCIL 2018 - 2019

Master
Dr S R E Sayampanathan

Assistant Master - Academic Affairs
Dr Teo Eng Kiong

Assistant Master - Administrative Affairs
Dr Khoo Kei Siong

Scribe
Dr Lai Fon Min

Bursar
Dr David Lye Chien Boon

Assistant Bursar
Dr Tay Jam Chin

Censor-in-Chief
Dr Yeo Jin Fei

Censors
Dr Chan Yew Weng
Dr Goh Yaw Chong
Dr Ho Kok Sun
Dr Lim Lay Cheng
Dr Alan Ng Wei Keong
Dr Wong Chiang Yin

APPOINTED COUNCIL MEMBERS

President, College of Anaesthesiologists
Dr Sophia Chew

President, College of Dental Surgeons
Dr Andrew Ow

President, College of Obstetricians and Gynaecologists
Dr Yong Tze Tein

President, College of Paediatrics and Child Health
Dr Liew Woei Kang

President, College of Physicians
Dr Chan Choong Meng

President, College of Radiologists
Dr Ian Tsou

President, College of Surgeons
Dr Chua Wei Chong

President, College of Emergency Physicians
Dr Goh Siang Hiong

President, College of Ophthalmologists
Dr Wong Tien Yin

President, College of Psychiatrists
Dr John Wong

President, College of Public Health & Occupational Physicians
Dr Vernon Lee

President, College of of Clinician Scientists
Dr Pierce Chow Kah Hoe

President, College of Clinician Educators
Dr Dujeepa Samarasekera

Chair, Chapter of Pathologists
Dr Inny Busmanis

Chair, Chapter of Intensivists
Dr Loo Chian Min

Chair, Chapter of Family Medicine Physicians
Dr Lee Kheng Hock

EX-OFFICIO

Editor, Annals
Dr Erle Lim

CO-OPTED MEMBERS

Dean, Academy Deanery
Dr Lim Shih Hui

Director, Office of Professional Affairs
Dr Benjamin Ng
HONG KONG ACADEMY OF MEDICINE
COUNCIL 2017 - 2018

OFFICERS

President
Professor Lau Chak-sing

Vice-President (General Affairs)
Dr Lau Chor-chiu

Vice-President (Education & Examinations)
Professor Gilberto K K Leung

Honorary Secretary
Professor Henry L Y Chan

Honorary Treasurer
Dr Chow Yu-fat

Editor
Professor Martin C S Wong

EX OFFICIO MEMBERS

Anaesthesiologists
Professor Cheung Chi-wai

Community Medicine
Dr Thomas H F Tsang

Dental Surgeons
Dr Robert P Y Ng

Emergency Medicine
Dr Axel Y C Siu

Family Physicians
Dr Angus M W Chan

Obstetricians & Gynaecologists
Dr Leung Wing-cheong

Ophthalmologists
Professor Jimmy S M Lai

Orthopaedic Surgeons
Professor Patrick S H Yung

Otorhinolaryngologists
Dr Victor Abdullah

Paediatricians
Professor Lau Yu-lung

Pathologists
Dr Michael H M Chan

Physicians
Professor Philip K T Li

Psychiatrists
Professor Eric Y H Chen

Radiologists
Dr Law Chun-key

Surgeons
Professor Paul B S Lai

ELECTED MEMBERS

Dr Chen Phoon-ping
Professor Gabriel M Leung
Dr Luk Hung-to
Dr Tang Wai-lun
Dr Clara W Y Wu
COLLEGE OF PHYSICIANS
ACADEMY OF MEDICINE OF MALAYSIA
COUNCIL 2016 - 2018

President	Dr Letchuman Ramanathan
Vice-President	Dr Goh Kim Yen
Immediate Past President	Professor Dato’ Dr Aminuddin Ahmad
Hon Secretary	Associate Professor Dr Bahariah Khalid
Hon Deputy Secretary	Professor Dr Mohd Sharir Mohamed Said
Hon Treasurer	Dr Richard Lim Boon Leong
Council Members
Professor Dato’ Dr Abdul Razak Mutallif
Dato’ Dr Azmillah Rosman
Dato’ Dr Joseph Eravelly
Senior Professor Dato’ Dr Khalid Yusoff
Dr Mohd Noh Idris
Datuk Dr Paras Doshi
Professor Dr Roslina Abdul Manap
Dr Sia Koon Ket
Dr Tan Soek Siam

MALAYSIAN ONCOLOGICAL SOCIETY
COUNCIL 2015 - 2018

President	Dr Matin Mellor
Honorary Secretary	Dr Muhammad Azrif bin Ahmad Annuar
Honorary Treasurer	Dr Tho Lye Mun
Council Members
Professor Dato’ Dr Fuad Ismail
Associate Professor Dr Ho Gwo Fuang
Dr Mastura Md Yusof
Associate Professor Dr Marniza Saad
Dr Azura Rozila Ahmad

Coopted Members
Dr Sucharit Prongprakyon
Dr Muthukkumaran Thiagarajan
## ORGANISING COMMITTEE

<table>
<thead>
<tr>
<th>Role</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chairperson</td>
<td>Associate Professor Dr Bahariah Khalid</td>
</tr>
<tr>
<td>Co-Chairpersons</td>
<td>Dr Matin Mellor</td>
</tr>
<tr>
<td>Hon Treasurer</td>
<td>Dr Richard Lim Boon Leong</td>
</tr>
<tr>
<td>Hon Secretary</td>
<td>Dr Nuur Habibah Ghazali</td>
</tr>
<tr>
<td>Publicity and Publications</td>
<td>Dr Liew Yuet Leng</td>
</tr>
<tr>
<td></td>
<td>Dr Sazlyna Mohd Sazly Lim</td>
</tr>
<tr>
<td>Logistics</td>
<td>Dr Chia Boon Hong</td>
</tr>
<tr>
<td></td>
<td>Dr Durga Arinandini</td>
</tr>
<tr>
<td></td>
<td>Dr Saiful Adni bin Abd Latif</td>
</tr>
<tr>
<td>Social</td>
<td>Dr Narissa Sulaiman Sahari</td>
</tr>
<tr>
<td></td>
<td>Dr Shaharudeen Kamaludeen</td>
</tr>
<tr>
<td></td>
<td>Dr Ummi Nadira Daut</td>
</tr>
<tr>
<td>Sponsorship and Exhibition</td>
<td>Dr Hazwani bt Aziz</td>
</tr>
<tr>
<td></td>
<td>Dr Premila Arul Arumugam</td>
</tr>
<tr>
<td></td>
<td>Dr Tho Lye Mun</td>
</tr>
</tbody>
</table>
COMMITTEES

SCIENTIFIC COMMITTEE

Chairperson
Dr Letchuman Ramanathan

Co-Chairperson
Dr Muhammad Azrif bin Ahmad Annuar

Committee Members
Professor Dato’ Dr Abdul Razak Muttalif
Dr Azura bt Deniel
Associate Professor Dr Bahariah Khalid
Dr Goh Kim Yen
Associate Professor Datuk Dr Ismail Sagap
Dr Mastura Md Yusof
Dr Sia Koon Ket
Dr Tho Lye Mun
INVITED FACULTY

Australia
Ghauri Aggarwal
Steven Kao

China
Lam Ka On
Martin Chi-Sang Wong

Germany
Wolfgang Janni

Singapore
Lalit Krishna
Lester Leong
Lim Geok Hoon
Sumbul Zaheer
Tan Yew Oo
Yap Yoon Sim

United Arab Emirates
Shaheenah Dawood

United Kingdom
Roisin Bevan

USA
Jhaveri Komal

Malaysia
A Rahman A Jamal
Abd Razak Ahmad
Aida Abdul Aziz
Asrul Akmal Shafie
Chai Wen Lin
Cheong Soon Keng
Flora Chong Li Tze
Feisul Idzwan Mustapha
Fuad Ismail
Gan Gin Gin
Hany Ariffin
Hayati Yaakup
Aaron Hiew Wi Han
Ho Gwo Fuang
Ismail Sagap
Jamalia Rahmat
Jameela Sathar
Krishnan Raman
Liam Chong Kin
John Low Seng Hooi
Mastura Md Yusof
Matin Mellor

Malaysia
Muhammad Azrif Annuar
Muthukkumaran Thiagarajan
Nik Muhd Aslan Abdullah
Nik Ritza Kosai Nik Mahmood
Nirmala Bhoo Pathy
Nor Hafizah Ahmad
Nor Saleha Ibrahim Tamim
Nur Aishah Taib
Pathmanathan Rajadurai
Raja Affendi Raja Ali
Ranjit Kaur
Shahnaz Murat
Shazril Imran Shaukat
Sri Ganesh Muthiah
Sucharit Prongprakyun
Tan Sen Mui
Teo Soo Hwang
Darren Teoh Choon Yu
Tho Lye Mun
Voon Pei Jye
Yoon Sook Yee

Singapore
Lalit Krishna
Lester Leong
Lim Geok Hoon
Sumbul Zaheer
Tan Yew Oo
Yap Yoon Sim

United Arab Emirates
Shaheenah Dawood

United Kingdom
Roisin Bevan

USA
Jhaveri Komal
Professor Dato’ Dr Khalid Abdul Kadir

Medical Research: A Matter of Life and Health

Citation by Tan Sri Dato’ Dr Yahya Awang

Professor Dr Khalid Abdul Kadir or Khalid, as he is widely known to his close friends in the medical fraternity, was born in Johor in 1948. He received his education at the Royal Military College then one of the top schools in Malaysia. At school, he had a brilliant academic record culminating in winning the prestigious Commandant’s Prize in RMC in 1968.

For his fine achievement he was awarded a government scholarship to read Medicine at Monash University, Melbourne, Australia and that was when I begin my association with the brilliant student. I have never met anyone since who radiated such continual positivity. As our professional relationship developed, I learned more about the man himself. He was brilliant, kind and exudes confidence. He had joined the Royal Military College as a young man and developed disciplined professionalism which remains his core personality.

Again he excels in medical school and he scored a double first-class honour in B. Med. Sc. 1973 and first-class honours in MBBS in 1975. It was no surprise that he was the Henry Hindlip Green Prize in Clinical Medicine and the Harriet Power Prize in Medicine. After graduation he worked in Melbourne where he was trained and obtained his postgraduate specialist degree in Endocrinology.

If there is a word to describe Khalid’s endeavour, in Academic and Life, it is the term “excellence”. Aristotle had some interesting thoughts on the subject. He said “We are what we repeatedly do. Excellence, then, is not an act but a habit”.

Yes, Khalid achieved excellence in his career and life and that is his habit.

He returned to Malaysia to serve his people and joined the Universiti Kebangsaan Malaysia (UKM) as a lecturer. As expected, he soon became Dean of the Medical Faculty and was promoted to Professor in 1990. In 2004, he retired from UKM and was then appointed as Professor of Medicine, Monash University Malaysia. Khalid’s research interests are in Stress and mechanisms of adaptation to stress by hormones. He has published more than 200 scientific articles on endocrinology and diabetes.

In 1992, he was elected President of the ASEAN Federation of Endocrine Societies. He was elected member of Malaysian Medical Council from 1986 till 2001, President of the Persatuan Diabetes Malaysia for five years from 1985 to 1990 and Master of the Academy of Medicine of Malaysia from 2006 to 2008. For his many academic achievements, he was awarded the SMJ in 1986, and DPMJ in 1988, and the JSM by The King of Malaysia in 1992.

He is married to Professor Datin Dr Norella Kong, a specialist in Nephrology, and has three sons. Apart from medicine, his other interest in life is fishing and collecting ducks.

I have the privilege and honour of presenting Professor Dato’ Dr Khalid Kadir who will share with us his views on “Medical Research: A Matter of Life and Health”.

Professor Dato’ Dr Khalid Abdul Kadir is also the recipient of the Lifetime Achievement Award 2018 of the College of Physicians, Academy of Medicine of Malaysia.
<table>
<thead>
<tr>
<th>Date</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>19th August 2016</td>
<td>DYMM Paduka Seri Sultan Perak Darul Ridzuan, Sultan Nazrin Muizzuddin Shah Ibni Almarhum Sultan Azlan Muhibbuddin Shah</td>
</tr>
<tr>
<td>26th August 2014</td>
<td>YB Datuk Seri Dr S Subramaniam on “Towards the Ministry of Health”</td>
</tr>
<tr>
<td>12th July 2012</td>
<td>Tan Sri Dato’ Dr Lin See-Yan on “It’s A Dangerous World Out There”</td>
</tr>
<tr>
<td>12th November 2010</td>
<td>Professor Dr Yeoh Eng Kiong on “Medicine - Back to the Future, Beyond Science”</td>
</tr>
<tr>
<td>31st July 2008</td>
<td>DYMM Raja Muda Perak Darul Ridzuan Raja Nazrin Shah on “Leadership”</td>
</tr>
<tr>
<td>24th August 2006</td>
<td>Professor Lim Pin on “Demands And Challenges Of Modern Medicine”</td>
</tr>
<tr>
<td>24th August 2003</td>
<td>Tan Sri Dato’ Dr Abu Bakar Suleiman on “Medical Professionalism: Maintaining The Distinction Between Medicine As A Profession And Medicine As A Commodity”</td>
</tr>
<tr>
<td>23rd August 2001</td>
<td>YABhg Dato’ Seri Dr Siti Hasmah Bte Hj Mohd Ali on “Women’s Health”</td>
</tr>
<tr>
<td>19th August 1999</td>
<td>Prof Tan Sri Dr Noordin Sopiee on “Malaysia - The Way Forward”</td>
</tr>
<tr>
<td>21st August 1997</td>
<td>YAB Datuk Seri Anwar Ibrahim, Deputy Prime Minister, on “Medicine As A Social Service”</td>
</tr>
<tr>
<td>10th August 1995</td>
<td>YB Datuk Amar Dr Hj Sulaiman b Hj Daud, Minister of Agriculture, on “Role Of Agriculture In Creating Values For The Country And Improving The Quality Of Life For The People Of Malaysia Towards The Year 2020”</td>
</tr>
<tr>
<td>11th August 1993</td>
<td>Sir Raymond Hoffenberg on “Training Doctors For The 21st Century - Have We Got It Right?”</td>
</tr>
<tr>
<td>3rd October 1991</td>
<td>Mr Robert Kuok on “A View Of The Asia-Pacific Economies In The Year 2010”</td>
</tr>
<tr>
<td>5th October 1989</td>
<td>DYMM Seri Paduka Baginda Yang Di-Pertuan Agong, Sultan Azlan Shah, on “Medicine, Ethics And Law”</td>
</tr>
<tr>
<td>15th October 1987</td>
<td>Prof Tan Sri T J Danaraj, Founder Dean of the Faculty of Medicine, University of Malaya, on “The Experience Of Medicine”</td>
</tr>
<tr>
<td>1st August 1985</td>
<td>YAB Dato’ Musa Hitam, Deputy Prime Minister, on “Tun Dr Ismail And The State Of Malaysia”</td>
</tr>
<tr>
<td>8th September 1983</td>
<td>Tan Sri DrTan Chee Khoon, former Leader of the Opposition, on ”Malayanisation Of The Medical Service And Postgraduate Medical Education In Malaysia”</td>
</tr>
<tr>
<td>4th December 1980</td>
<td>YB Tun Tan Siew Sin, Minister of Finance, on “National Unity”</td>
</tr>
<tr>
<td>30th September 1978</td>
<td>Dr Patrick A Ongley, President of China Medical Board of New York, on “Organisational Responsibilities Involved In The Granting Of Postgraduate Medical Diplomas And Degrees In Malaysia”</td>
</tr>
<tr>
<td>19th August 1976</td>
<td>YAB Dato’ Seri Dr Mahathir Mohamad, Deputy Prime Minister, on “Coordination In Higher Education”</td>
</tr>
<tr>
<td>6th September 1974</td>
<td>YAA Tun Mohd Suffian b Haji Mohd Hashim, Lord President of the Judiciary, on “Tun Dr Ismail And His Contributions”</td>
</tr>
</tbody>
</table>

The Master and Council Members of the Academy of Medicine of Malaysia extend their grateful thanks to the Kuok Foundation Berhad for its kind and generous support of the Tun Dr Ismail Orations.
The T J Danaraj Oration commemorates Tan Sri Professor T J Danaraj’s life and contributions. Professor Danaraj was an extraordinary Mentor and Teacher of Medicine. He was a visionary and pioneer in medical education and research in Singapore and Malaysia. He established the first Medical School in the country in 1964 having watched over every phase of its development - a Medical School that quickly achieved international acclaim. He had motivated generations of students in the practice of medicine. He taught values and he taught learning.

His students hold him in highest honour for the way he nurtured and moulded them. It is thus so fitting that this T J Danaraj Oration is being delivered by one of his students, one who has risen to eminence in his own lifelong dedication to medical education, medical research, and service.

Professor Dr Victor Lim is a Microbiologist, specialising on antimicrobial resistance and infectious diseases. He is currently Professor of Pathology and Pro Vice-Chancellor at the International Medical University in Kuala Lumpur. He is also a member of its Board of Governors.

Professor Dr Victor Lim was a student at the prestigious Victoria Institution in Kuala Lumpur. He then obtained a Federal Scholarship to read medicine at the University of Malaya and obtained his medical degree (MBBS) in 1974. He was awarded an MSc in Medical Microbiology (with distinction) by the University of London in 1978, and became a member of the Royal College of Pathologists in 1981.

He was previously Professor of Microbiology and Deputy Dean at the Faculty of Medicine of Universiti Kebangsaan Malaysia, and Director of the Infectious Diseases Research Centre at the Institute for Medical Research in Kuala Lumpur.

Upon retirement from this position he joined the International Medical University. He has been a member of the university’s senior management committee as Executive Dean from 2004 to 2011, as Vice President for Education from 2011 then as Pro Vice-Chancellor from 2016. He was also Director of the IMU Centre for Education from 2009 to 2015. He is still actively teaching candidates for the Master of Pathology at the Universiti Kebangsaan Malaysia. Professor Dr Lim has served as President of the Western Pacific Society of Chemotherapy (2004-2008), was the Master of the Academy of Medicine of Malaysia (2008-2011) and the President of the Malaysian Society for Infectious Diseases and Chemotherapy (1999-2003).

He is a Fellow of the Royal College of Pathologists, a Fellow of the Academy of Medicine of Malaysia, a Fellow of the Academy of Medicine, Singapore, an Honorary Fellow of the Academy of Family Physicians and a Fellow of the Academy of Sciences of Malaysia. He was Editor-in-Chief of the Malaysian Medical Journal from 1991-1998. He is also a member of several governmental committees, including the National Antibiotic and Infection Control Committee and a member of the Malaysian Medical Council.

Professor Dr Victor Lim has presented close to 400 papers at local and international meetings and is frequently invited as speaker at conferences. He has written several books and monographs.

Professor Dr Victor Lim has a particular interest in medical education and has spoken and written extensively on this.

It is thus indeed with much anticipation that I welcome Professor Dr Victor Lim to address this very urgent matter in our country today.

“How many medical students - Matching the number and types of students to a country’s needs”
CHAN CHOONG MENG
President, College of Physicians, Singapore
Dr Chan received his Medical Degree from University of Newcastle-Upon-Tyne, United Kingdom and trained as a nephrologist in University College Hospital, London, UK. He is currently President of the College of Physicians, Singapore from 2015.

He is the Group Director of Education for SingHealth and senior Associate Dean, Duke NUS Medical School since 2018. He was Singapore General Hospital (SGH) Campus Educator Director from 2014 to 2017. He was also the Vice Chair of Education for Medicine ACP from 2012 to 2016. Dr Chan served as Head of Department of Renal Medicine from 2008 to 2014 and as the Associate Designated Institutional Official for SGH from 2012 to 2014. He is also an Adjunct Associate Professor at both National University Singapore (NUS) YLL School of Medicine and Duke NUS Medical School. His research interest has been chronic kidney disease, diabetic nephropathy and IgA nephropathy.

MICHAEL H M CHAN
President, The Hong Kong College of Pathologists
After graduation from The Chinese University of The Hong Kong, Dr Chan joined the Department of Chemical Pathology at Prince of Wales Hospital (PWH). He has obtained Fellowships from The Royal College of Pathologists of Australasia, The Hong Kong College of Pathologists, the Hong Kong Academy of Medicine and Specialist status in Chemical Pathology under the Medical Council of Hong Kong. He is the current President of The Hong Kong College of Pathologists. His current appointment in Hospital Authority of Hong Kong includes Chairman of the Coordinating Committee in Pathology, Cluster Coordinator in Pathology of New Territories East Cluster and Consultant Chemical Pathologist at PWH.

ANGUS M W CHAN
President, The Hong Kong College of Family Physicians
Dr Angus Chan graduated from the University of Glasgow, UK. Dr Chan is actively involved in the training and examination of The Hong Kong College of Family Physicians. He was the Chairman of the Specialty Examination Board from 2007 to 2010, Vice President (Education and Examination) from 2011 to 2014 and is the President of the College from 2015 till now.

He is a Family Physician trainer and is the Honorary Clinical Associate Professor, Department of Family Medicine and Primary Care, The University of Hong Kong. He is the Chairman, Advisory Committee on Antibiotic Stewardship in Primary Care, Central for Health Protection, Hong Kong.

Dr Chan is currently in private practice. He is the Medical Director of a renowned medical group and is also the medical consultant of two large insurance companies in Hong Kong.

CHEUNG CHI-WAI
President, The Hong Kong College of Anaesthesiologists
Professor Cheung is currently the Clinical Professor in the Department of Anaesthesiology, The University of Hong Kong and Assistant Dean of Li Ka Shing Faculty of Medicine, The University of Hong Kong. His research interests include basic and clinical pain medicine. He has published extensively in peer-reviewed scientific journals of Anaesthesiology and Pain Medicine. He is an editorial board member of the British Journal of Anaesthesia and the Section Editor of Pain Practice. He is the current President of The Hong Kong College of Anaesthesiologists and a Past President of the Society of Anaesthetists of Hong Kong.
CITATIONS - FELLOWS OF THE ACADEMY OF MEDICINE OF MALAYSIA

CHUA WEI CHONG  
President, College of Surgeons, Singapore  
Dr Chua started his professional medical career in the Singapore Armed Forces and completed his final tour as a Colonel and Chief of HQ Army Medical Services in 2012. He is currently a senior consultant general surgeon at the Tan Tock Seng Hospital with special interest in trauma surgery. Dr Chua also holds a number of key appointments including President, College of Surgeons, Singapore, Clinical Director, National Trauma Unit and Director, Surgical Sciences Training Centre. He is very passionate about teaching and passing good values to the next generation of surgeons. He enjoys collecting Lego in his free time.

ALEJANDRO C DIZON  
President, Philippine College of Surgeons  
Dr Dizon a General Surgeon with a special interest and focus in Breast and Thyroid Surgery for 26 years and for the past 16 years has pursued a personal and professional interest and advocacy on Patient Safety. He is a past President of the Philippine Association of Training Officers in Surgery and Chairman of the Philippine Board of Surgery. He is currently an Assistant Professor in the University of the East Ramon Magsaysay Memorial Medical Center, Vice President and Chief Quality Officer for St. Luke’s Medical Center in the Philippines, Physician-Consultant with Joint Commission International and President of the Philippine College of Surgeons.

MARY HORGAN  
President, Royal College of Physicians of Ireland  
Professor Mary Horgan is President of the Royal College of Physicians of Ireland, former Dean of the School of Medicine, University College Cork, and Consultant Physician in Infectious Diseases at Cork University Hospital. She graduated from University College Dublin in 1986 and trained in Internal Medicine in Ireland and Infectious Diseases at the Washington University School of Medicine, St Louis, USA.

Professor Horgan is a Government appointee on a number of health service-related national boards, a former President of the Infectious Diseases Society of Ireland and a member of the Governing Body of University College Cork, Ireland. Professor Horgan is the first female President of RCPI since its founding in 1654.

PAUL B S LAI  
President, The College of Surgeons of Hong Kong  
Professor Paul Lai is currently the President of The College of Surgeons of Hong Kong. He has extensive experience in surgical training and examinations. Professor Lai serves as the Director of the Office of Medical Education at The Chinese University of Hong Kong. His office oversees the curriculum and teaching administration of the medical programme. Professor Lai is an academic surgeon specialised in hepato-biliary and pancreatic surgery. His research interests include basic and clinical sciences and surgical outcome research. He is also the Director of the Surgical Outcome Monitoring and Improvement Programme (SOMIP) at the Hospital Authority, Hong Kong.
CITATIONS - FELLOWS OF THE ACADEMY OF MEDICINE OF MALAYSIA

JIMMY S M LAI
President, The College of Ophthalmologists of Hong Kong
Professor Lai is currently the Acting Head of the Department of Ophthalmology at the University of Hong Kong, the Chief of Service of the Department of Ophthalmology, Queen Mary Hospital, the Chair of Specialty of the Department of Ophthalmology of the Gleneagles (Hong Kong) Hospital. He is the President of The Hong Kong College of Ophthalmologists and executive member of the Asian Foundation for the Prevention of Blindness. He was granted the Distinguished Service Award and the DeOcampel Lecture Award by the Asian-Pacific Academy of Ophthalmology in 2005 and 2015 respectively.

LAU CHAK-SING
President, Hong Kong Academy of Medicine
Professor Lau Chak-sing is President of the Hong Kong Academy of Medicine. He is Chair and Daniel C K Yu Professor in Rheumatology and Clinical Immunology, Director of the Bau Institute of Medical and Health Sciences Education, and Associate Dean (Teaching & Learning) of the Li Ka Shing Faculty of Medicine, at The University of Hong Kong. He is Founding Chairman of the Hong Kong Arthritis and Rheumatism Foundation, and was President of the Asia Pacific League of Associations for Rheumatology (APLAR) (2006-2008). He also served as Editor-in-Chief of the APLAR Journal of Rheumatology/International Journal of Rheumatic Diseases (2004-2012).

LAU CHOR-CHIU
Vice-President (General Affairs), Hong Kong Academy of Medicine
Dr Lau Chor-chiu is an Emergency Medicine Specialist, currently the Vice-President (General Affairs) of the Hong Kong Academy of Medicine, Cluster Chief Executive of Hong Kong East Cluster of Hospital Authority (HA), and Deputy Chairman of Hong Kong Red Cross. He is a member of the Medical Council of Hong Kong and Honorary Associate Professor of Li Ka Shing Faculty of Medicine of The University of Hong Kong. He was also Honorary Secretary of the Hong Kong Academy of Medicine (2012-2016), and the President of Hong Kong College of Emergency Medicine (2005-2011).

VERNON LEE
President, College of Public Health and Occupational Physicians, Academy of Medicine, Singapore
Associate Professor Vernon Lee is a preventive medicine physician and President of the College of Public Health and Occupational Physicians, Academy of Medicine, Singapore. He is also Director of the Communicable Diseases Division, Ministry of Health, Singapore, and adjunct Associate Professor at the Saw Swee Hock School of Public Health, National University of Singapore.

Associate Professor Lee graduated from the National University of Singapore. He also holds a PhD in epidemiology from the Australian National University, and a Master in Public Health and a Master of Business Administration degrees from the Johns Hopkins University, USA.
PHILIP K T LI
President, Hong Kong College of Physicians

Professor Philip Li is the President of the Hong Kong College of Physicians. He is the Chief of Nephrology and Consultant Physician of the Department of Medicine and Therapeutics at the Prince of Wales Hospital, Hong Kong and Honorary Professor of Medicine at the Chinese University of Hong Kong. Professor Li is the President of the Asian Pacific Society of Nephrology and the Immediate Past President of the International Society for Peritoneal Dialysis. He is also the current President of the International Association of Chinese Nephrologists (IACN) and Chairman of the Central Renal Committee of Hospital Authority of Hong Kong.

JOHNNY MAHLANGU
President, College of Pathologists of the Colleges of Medicine of South Africa

Professor Johnny Mahlangu is the President of the College of Pathologists of the Colleges of Medicine of South Africa. He is Professor of Haematology and Head of the School of Pathology in the Faculty of the Health Sciences at the University of the Witwatersrand in Johannesburg, South Africa. He is also Director of the Bleeding Disorders Unit, which encompasses the Adult Haemophilia Comprehensive Care Centre and Head of Clinical Haematology Services at the Charlotte Maxeke Johannesburg Academic Hospital.

Professor Mahlangu received his undergraduate training in science and medicine at the University of the Witwatersrand. He specialised in haematology and sub-specialised in clinical haematology through the National Colleges of Medicine of South Africa. He is involved with clinical research in bleeding disorders and diagnostic pathology technology.

MOHAMAD SIDIK
President, Indonesian Ophthalmologists Association

Dr Mohamad Sidik has been a member of the Department of Ophthalmology, Faculty of Medicine, Universitas Indonesia since 1994. He qualified as an ophthalmologist in 1993 and pursued a fellowship programme in the field of Neuro-Ophthalmology at Universitat Augenklinik, University of Vienna, Austria in 1993. He became head of Department of Ophthalmology in the year 2004 till 2008.

In the Asia Pacific region, he acted as Indonesian Regional Secretary for Asia-Pacific Association of Ophthalmology for the period 2010-2016. He has been a council member of Asia Neuro-Ophthalmology Society since 2003 and Chairman of The 7th Asia Neuro-Ophthalmology Society Meeting that was held in Bali in the year 2013.

Starting from 2016, he is elected as President of Indonesian Ophthalmologists Association (Perdami) for the period 2016-2019.
CITATIONS - FELLOWS OF THE ACADEMY OF MEDICINE OF MALAYSIA

ROBERT P Y NG
President, The College of Dental Surgeons of Hong Kong
Dr Robert Ng graduated with a BDS degree from the University of London in 1984. He worked in general practice in London from 1985 to 1997. In 1997, he embarked on specialist training in endodontics at the Eastman Dental Institute in London and completed his training at the Faculty of Dentistry, University of Hong Kong.

Dr Ng is a specialist in Endodontics registered with the Dental Council of Hong Kong and works in private practice. He is currently the President and Chairman of the Specialty Board in Endodontics of the College of Dental Surgeons of Hong Kong, a member of the Dental Council of Hong Kong and a member of the Board of Governors of the Prince Philip Dental Hospital.

DUJEEPA D SAMARASEKERA
President, College of Clinician Educators, Academy of Medicine, Singapore
Dr Samarasekera is the Director, Centre for Medical Education, Yong Loo Lin School of Medicine, National University of Singapore and Senior Consultant in Medical Education, Ministry of Health Singapore. He has been involved in curriculum development, quality assurance and accreditation and faculty development of health professional courses at both undergraduate and postgraduate level. He is the Course Director of the Masters in Health Professions Education - Singapore which is a collaboration with University of Maastricht, Netherlands. He is the Editor-in-Chief of The Asia Pacific Scholar (TAPS) journal and serves on the editorial advisory boards of Annals of Academic Medicine Singapore, South East Asian Journal of Medical Education (SEAJME), Korean Journal of Medical Education and AMEE online journal MedEd Publish. He is also President of the College of Clinician Educators, AMS and the President-Elect of the Western Pacific Association of Medical Education. He serves in many international medical education organisations and has published extensively in peer-reviewed medical education journals as well as authored book chapters relating to Medical and Health Professional Education.

AXEL Y C SIU
President, Hong Kong College of Emergency Medicine
Dr Siu has been a Fellow of the Hong Kong College of Emergency Medicine and Fellow of the Hong Kong Academy of Medicine (Emergency Medicine) since 2000. Dr Siu is currently a Consultant in the Accident and Emergency Department, Ruttonjee Hospital and Medical Director of Fire and Ambulance Services Academy.

Dr Siu is the President of the Hong Kong College of Emergency Medicine, Chairman of Resuscitation Council of Hong Kong, Secretary of Asian Society for Emergency Medicine and Chairman of Health and Care Service Management Committee, Hong Kong Red Cross. Dr Siu was also awarded the Order of International Federation of Emergency Medicine in 2016.

THOMAS H F TSANG
President, Hong Kong College of Community Medicine
Dr Tsang obtained his medical degree at the University of Hong Kong in 1990. He graduated with a Masters of Public Health degree from Johns Hopkins University (USA) in 1992. He obtained his Fellowship in Community Medicine under the Hong Kong Academy of Medicine in 1999.

Dr Tsang joined the Department of Health, HKSAR Government between 1992 and 2012, and became the Controller of the Centre for Health Protection during 2007-2012. His work experience and publications have mainly been on the prevention and control of infectious diseases. He took an active role in managing several major epidemics, including avian influenza (H5N1) in 1997, SARS in 2003, and pandemic influenza A(H1N1) in 2009. He has lectured extensively in local and international conferences, and published over 30 scientific papers and book chapters.

Presently, Dr Tsang is the President of the Hong Kong College of Community Medicine.
PATRICK S H YUNG
President, The Hong Kong College of Orthopaedic Surgeons

Professor Patrick Yung is a world recognised leader in the field of orthopaedic sports medicine. Professor and Chief of the Sports Medicine Team, Department of Orthopaedics and Traumatology, also the Director of the Hong Kong Jockey Club Sport Medicine and Health Science Centre, Faculty of Medicine, The Chinese University of Hong Kong.

He is an Honorary Consultant and Specialist in Orthopaedic Surgery, Department of Orthopaedics and Traumatology, Prince of Wales Hospital.

Professor Yung is currently the President of The Hong Kong College of Orthopaedic Surgeons (HKCOS) and The Asian Federation of Sports Medicine (AFSM).
## Programme Summary

<table>
<thead>
<tr>
<th>Date</th>
<th>27th July 2018 (Friday)</th>
<th>28th July 2018 (Saturday)</th>
<th>29th July 2018 (Sunday)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0700 - 0730</td>
<td>Registration</td>
<td>Joint Council Meeting of the Academies (by invitation only)</td>
<td></td>
</tr>
<tr>
<td>0730 - 0800</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0800 - 0830</td>
<td>SYMPOSIA (1A - 1C)</td>
<td></td>
<td>SYMPOSIA (5A - 5C)</td>
</tr>
<tr>
<td>0830 - 0900</td>
<td>SYMPOSIA (2A - 2C)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0900 - 0930</td>
<td>Tea / Booth Visit</td>
<td></td>
<td>Tea / Booth Visit</td>
</tr>
<tr>
<td>0930 - 1000</td>
<td>Lunch Symposium 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1000 - 1030</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1030 - 1100</td>
<td>Friday Prayers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1100 - 1130</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1130 - 1200</td>
<td>SYMPOSIA (3A - 3C)</td>
<td>SYMPOSIA (3A - 3C)</td>
<td></td>
</tr>
<tr>
<td>1200 - 1230</td>
<td>Lunch Symposium 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1230 - 1300</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1300 - 1330</td>
<td>SYMPOSIA (4A - 4C)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1330 - 1400</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1400 - 1430</td>
<td>PLENARY 1</td>
<td>PLENARY 3</td>
<td></td>
</tr>
<tr>
<td>1430 - 1500</td>
<td>KEYNOTE ADDRESS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1500 - 1530</td>
<td>Tea / Booth Visit</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1530 - 1600</td>
<td>OPENING CEREMONY</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1600 - 1630</td>
<td>Fellowship Conferment &amp; Induction Ceremony</td>
<td></td>
<td>Tea Symposia 3 &amp; 4</td>
</tr>
<tr>
<td>1630 - 1700</td>
<td>22nd Tun Dr Ismail Oration</td>
<td></td>
<td>Tea / Booth Visit</td>
</tr>
<tr>
<td>1700 - 1730</td>
<td>WELCOME RECEPTION</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1730 - 1800</td>
<td>Presidential Dinner of 52nd Malaysia-Singapore Congress of Medicine &amp; Jade Ribbon Gala Event (by invitation only)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1930 - 2200</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### 26th July 2018 (Thursday)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>1300 - 1730 hrs</td>
<td>Pre-Congress Workshop 1</td>
</tr>
<tr>
<td></td>
<td>Pre-Congress Workshop 2 - Management of Immunotherapy Toxicity</td>
</tr>
</tbody>
</table>
PRE-Congress Workshop 1

Date: 26th July 2018 (Thursday)
Time: 1300 - 1730 hrs
Venue: Tamingsari 1 & 2, Royale Chulan Kuala Lumpur, Malaysia
Chairperson: Bahariah Khalid

PROGRAMME
1300 - 1400 Registration
1400 - 1500 War on Cancer Launching
1500 - 1530 Indwelling Pleural Catheter for Lung Malignancies
   Mohamed Faisal Abd Hamid
1530 - 1600 Chemotherapy Spillage: What Do You Need To Know?
   Wong Shu Ping
1600 - 1630 Radiological Intervention in Malignancy
   Basri Johan Jeet Abdullah
1630 - 1700 Chemoport Insertion
   Rohaizak Muhammad
1700 - 1730 Grand Ward Round
   Bahariah Khalid

PRE-Congress Workshop 2

Management of Immunotherapy Toxicity

Date: 26th July 2018 (Thursday)
Time: 1300 - 1730 hrs
Venue: Tamingsari 2, Royale Chulan Kuala Lumpur, Malaysia

PROGRAMME
1300 - 1400 Registration
1400 - 1500 War on Cancer Launching
1500 - 1520 Introduction to the Immune System
   Sharmili Vidyadaran
1520 - 1600 Pathophysiology of Immune-Related Toxicity and Indications of Immunotherapy
   Wan Zamaniah Wan Ishak
1600 - 1640 Practical Management of Immune Related Adverse Events
   Marniza Saad
1640 - 1730 Case Discussions
   Patricia Shamani / Hadi Abd Jalil
### DAILY PROGRAMME
**27TH JULY 2018 (FRIDAY)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
<th>Chairman</th>
<th>Speaker 1</th>
<th>Speaker 2</th>
<th>Speaker 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>0700 - 0800</td>
<td>Registration</td>
<td>Tamingsari 1 &amp; 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0800 - 0930</td>
<td><strong>SYMPOSIUM 1A</strong></td>
<td>Tamingsari 3</td>
<td><strong>Upper Gastrointestinal Cancer</strong></td>
<td><strong>Chairperson:</strong> Azura Deniel</td>
<td><strong>Chairperson:</strong> Bahariah Khalid</td>
<td><strong>Hereditary Cancer</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Upper Gastrointestinal Cancer</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>Chairperson:</strong> Muhammad Azrif Annuar</td>
</tr>
<tr>
<td></td>
<td><strong>Chairperson:</strong> Raja Affendi Raja Ali</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0800 - 0830</td>
<td><strong>Symposium 1A</strong></td>
<td>Tamingsari 3</td>
<td><strong>Is There a Role for Mesenchymal Stem Cells in Managing Blood Cancers</strong></td>
<td><strong>Chairperson:</strong> Cheong Soon Keng</td>
<td><strong>Radiation Therapy in Lymphomas</strong></td>
<td><strong>Enabling Access to Genetic Counselling Services in Malaysia</strong></td>
</tr>
<tr>
<td>0830 - 0900</td>
<td><strong>Symposium 1B</strong></td>
<td>Tamingsari 2</td>
<td><strong>Evolution of Adjuvant Therapy for Gastric Cancer</strong></td>
<td><strong>Chairperson:</strong> Lam Ka On</td>
<td><strong>Radiation Therapy in Lymphomas</strong></td>
<td><strong>Somatic Gene Testing: Preparing for the Revolution</strong></td>
</tr>
<tr>
<td>0900 - 0930</td>
<td><strong>Symposium 1C</strong></td>
<td>Tun Sri Lanang 1</td>
<td><strong>Is There a Role for Mesenchymal Stem Cells in Managing Blood Cancers</strong></td>
<td><strong>Chairperson:</strong> Cheong Soon Keng</td>
<td><strong>Radiation Therapy in Lymphomas</strong></td>
<td><strong>Somatic Gene Testing: Preparing for the Revolution</strong></td>
</tr>
<tr>
<td>0930 - 1000</td>
<td><strong>Symposium 2A</strong></td>
<td>Tamingsari 2</td>
<td><strong>Endoscopic Approach and Advancement in Lymphadenectomy in UGI Malignancies</strong></td>
<td><strong>Chairperson:</strong> Nik Ritza Kosai Nik Mahmood</td>
<td><strong>Radiation Therapy in Lymphomas</strong></td>
<td><strong>Somatic Gene Testing: Preparing for the Revolution</strong></td>
</tr>
<tr>
<td>1000 - 1030</td>
<td><strong>Symposium 2B</strong></td>
<td>Tun Sri Lanang 1</td>
<td><strong>Translation Research in CRC: From Bench to Bedside</strong></td>
<td><strong>Chairperson:</strong> Cheong Soon Keng</td>
<td><strong>Radiation Therapy in Lymphomas</strong></td>
<td><strong>Somatic Gene Testing: Preparing for the Revolution</strong></td>
</tr>
<tr>
<td>1030 - 1100</td>
<td><strong>Symposium 2C</strong></td>
<td>Tun Sri Lanang 1</td>
<td><strong>Multidisciplinary Management of Colorectal Cancer</strong></td>
<td><strong>Chairperson:</strong> Sia Koon Ket</td>
<td><strong>Radiation Therapy in Lymphomas</strong></td>
<td><strong>Somatic Gene Testing: Preparing for the Revolution</strong></td>
</tr>
<tr>
<td>1100 - 1130</td>
<td><strong>Symposium 3</strong></td>
<td>Tun Sri Lanang 1</td>
<td><strong>Is There a Role for Mesenchymal Stem Cells in Managing Blood Cancers</strong></td>
<td><strong>Chairperson:</strong> Cheong Soon Keng</td>
<td><strong>Radiation Therapy in Lymphomas</strong></td>
<td><strong>Somatic Gene Testing: Preparing for the Revolution</strong></td>
</tr>
<tr>
<td>1100 - 1130</td>
<td><strong>Symposium 3</strong></td>
<td>Tun Sri Lanang 1</td>
<td><strong>Evolution of Adjuvant Therapy for Gastric Cancer</strong></td>
<td><strong>Chairperson:</strong> Lam Ka On</td>
<td><strong>Radiation Therapy in Lymphomas</strong></td>
<td><strong>Somatic Gene Testing: Preparing for the Revolution</strong></td>
</tr>
</tbody>
</table>

**Tea / Booth Visit**
## DAILY PROGRAMME
### 27th July 2018 (Friday)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
</table>
| 1130 - 1230 | **LUNCH SYMPOSIUM 1** *(A MENARINI)*  
Cancer Pain Management - What’s New?  
Ghauri Aggarwal | Tamingsari 1 & 2 |
| 1230 - 1400 | Friday Prayers                                                                                |                  |
| 1400 - 1430 | **PLENARY 1**  
Chairperson: Muhammad Azrif Annuar  
Cancer Treatment Over the Past Three Decades: Have We Made Progress?  
Tan Yew Oo | Tamingsari 1 & 2 |
| 1430 - 1500 | **KEYNOTE ADDRESS**  
Chairperson: Letchuman Ramanathan  
National Cancer Strategic Care Plan in Malaysia  
Shahnaz Murat | Tamingsari 1 & 2 |
| 1500 - 1530 | Tea / Booth Visit                                                                             |                  |
| 1530 - 1730 | **OPENING CEREMONY**  
Fellowship Conferment & Induction Ceremony  
22nd Tun Dr Ismail Oration  
Medical Research: A Matter of Life and Health  
Khalid Abdul Kadir | Tamingsari 1 & 2 |
| 1730 - 1800 | Welcome Reception                                                                             | Tamingsari 3      |
# Daily Programme

## 28th July 2018 (Saturday)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>0700 - 0800</td>
<td>Joint Council Meeting of the Academies <em>(by invitation only)</em></td>
<td>Executive Board Room</td>
</tr>
</tbody>
</table>
| 0800 - 0840 | **PLENARY 2**  
Chairperson: Bahariah Khalid  
Cancer Management Outcome: Where Does Malaysia Stand?  
Matin Mellor                     | Tamingsari 1 & 2 |
| 0840 - 0910 | **4th T J Danaraj Oration**  
How Many Medical Students? Can We Get it Right?  
Victor Lim                     | Tamingsari 1 & 2 |
| 0910 - 0950 | **TEA SYMPOSIUM 1 (ELI LILLY)**  
Management of Advanced / Metastatic Gastric Cancer  
*Nik Muhd Aslan Abdullah / Ho Gwo Fuang*  
**TEA SYMPOSIUM 2 (NOVARTIS)**  
Chairperson: Azura Rozila Ahmad  
Lower Dose with Similar Systemic Exposure in Advanced NSCLC, a Myth or a Reality?  
Voon Pei Jye              | Tamingsari 1 & 2 |
| 0950 - 1010 | Tea / Booth Visit                                                                         |                |
| 1010 - 1140 | **SYMPOSIUM 3A**  
Breast Cancer  
Chairperson: Yip Cheng Har  
**SYMPOSIUM 3B**  
Lung Malignancies  
Chairperson: Roslina Abdul Manap  
**SYMPOSIUM 3C**  
Miscellaneous  
Chairperson: Ahmad Izuanuddin Ismail  
**SYMPOSIUM 3C**  
Lower Dose with Similar Systemic Exposure in Advanced NSCLC, a Myth or a Reality?  
Voon Pei Jye              | Tamingsari 1 & 2 |
| 1110 - 1140 | Advances in Breast Cancer Surgery  
Limb Geok Hoon                                                                 | Tamingsari 3 |
| 1200 - 1330 | **LUNCH SYMPOSIUM 2 (NOVARTIS)**  
A New Era in Treatment of HR+HER2-ve Advanced Breast Cancer  
Chairperson: Matin Mellor  
MONALEUSA 2 Trial (Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer)  
Wolfgang Janni  
MONALEUSA-2 Asian Subset - A Subgroup Analysis from MONALEUSA-2  
Yoon Pei Jye  
Q & A Session  
Ribociclib Launch Activity  
**LUNCH SYMPOSIUM 3 (MSD)**  
Current Immunotherapy Landscape in NSCLC and Future Directions  
Steven Kao  
**Presidents’ Round Table** *(by invitation only)*  
| Tamingsari 1 & 2 |

*NOVARTIS*  
*MSD*
### 28th July 2018 (Saturday)

#### 1400 - 1430 PLENARY 3

**Chairperson:** Letchuman Ramanathan  
**Compulsory Cancer Screening Program in UK - Lessons Learnt**  
*Roisin Bevan*

<table>
<thead>
<tr>
<th>Time</th>
<th>Symposia</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>1430 - 1600</td>
<td>SYMPOSIUM 4A</td>
<td>Tamingsari 1 &amp; 2</td>
</tr>
<tr>
<td>1430 - 1500</td>
<td>SYMPOSIUM 4B</td>
<td>Tamingsari 3</td>
</tr>
<tr>
<td>1500 - 1530</td>
<td>DEBATE</td>
<td>Tun Sri Lanang 1</td>
</tr>
<tr>
<td>1530 - 1600</td>
<td>SYMPOSIUM 4C</td>
<td>Tun Sri Lanang 1</td>
</tr>
</tbody>
</table>

#### 1430 - 1600 SYMPOSIUM 4A

**Lung Malignancies**  
**Chairperson:** Razak Muttalif

- Role of Radiotherapy in NSCLC  
  *Tho Lye Mun*

- Neoadjuvant Chemotherapy - Choosing who Benefits  
  *Mastura Md Yusof*

#### 1430 - 1500 SYMPOSIUM 4B

**Breast Cancer**  
**Chairperson:** Ismail Sagap

- Adjuvant Chemotherapy: Selecting the Right Regimen for the Right Patient  
  *Shaheenah Dawood*

- Adjuvant Endocrine Therapy  
  *Darren Teoh Choon Yu*

#### 1500 - 1530 DEBATE

**Treating Targetable Mutations in Lung Cancer - Should We Sequence Our Tyrosine-Kinase Inhibitors?**  
*Proposer: Voon Pei Jye Opposer: Sucharit Prongprakyn*

#### 1530 - 1600 SYMPOSIUM 4C

**Palliative / Supportive Care**  
**Chairperson:** Sia Koon Ket

- “Continuing Care till the Very End - The Duty of a Doctor”  
  *Aaron Hiew Wi Han*

- Principles of Prognostication in Advanced Cancer  
  *Lalit Krishna*

- Cancer Pain - Making It Less  
  *Hayati Yaakup*

#### 1600 - 1640 TEA SYMPOSIUM 3 (ROCHE)

**A Personalised Approach to Treatment Through Comprehensive Genomic Profiling - A Focus in Breast Cancer**  
*Narin Voravud*

#### 1600 - 1640 TEA SYMPOSIUM 4 (PFIZER)

**Navigating with CDk4/6i: What it Meant to Me and My Patients for the Past Three Years**  
*Jhaveri Komal*

#### 1640 - 1700 Tea / Booth Visit

#### 1930 - 2200 Presidential Dinner of 52nd Malaysia-Singapore Congress of Medicine & Jade Ribbon Gala Event *(by invitation only)*
# Daily Programme

## 29th July 2018 (Sunday)

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Symposium Abar</th>
<th>Chairperson</th>
<th>Symposium B</th>
<th>Chairperson</th>
<th>Symposium C</th>
<th>Chairperson</th>
</tr>
</thead>
<tbody>
<tr>
<td>0800 - 0930</td>
<td>Tamingsari 1 &amp; 2</td>
<td><strong>SYMPOSIUM 5A</strong></td>
<td>Head and Neck Malignancies</td>
<td><strong>SYMPOSIUM 5B</strong></td>
<td>Cancer Survivorship</td>
<td><strong>SYMPOSIUM 5C</strong></td>
<td>Miscellaneous</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Chairperson: Vincent Phua</td>
<td>Chairperson: Shaharudeen Kamaludeen</td>
<td></td>
<td>Chairperson: Matin Mellor</td>
<td></td>
</tr>
<tr>
<td>0800 - 0830</td>
<td></td>
<td><strong>SYMPOSIUM 5A</strong></td>
<td><strong>SYMPOSIUM 5A</strong></td>
<td>Head and Neck Malignancies</td>
<td><strong>SYMPOSIUM 5B</strong></td>
<td>Cancer Survivorship</td>
<td><strong>SYMPOSIUM 5C</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Chairperson: Vincent Phua</td>
<td>Chairperson: Shaharudeen Kamaludeen</td>
<td></td>
<td>Chairperson: Matin Mellor</td>
<td></td>
</tr>
<tr>
<td>0830 - 0900</td>
<td></td>
<td><strong>SYMPOSIUM 5A</strong></td>
<td>Update on Surgical Management</td>
<td>Dealing with Fear of Cancer</td>
<td>Cancer Screening in Malaysia</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>in Head and Neck Cancer</td>
<td>Recurrence</td>
<td>Nor Saleha Ibrahim Tamim</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>SYMPOSIUM 5A</strong></td>
<td><strong>SYMPOSIUM 5B</strong></td>
<td>Update on Surgical Management</td>
<td><strong>SYMPOSIUM 5B</strong></td>
<td>Cancer Survivorship</td>
<td><strong>SYMPOSIUM 5C</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>in Head and Neck Cancer</td>
<td>Dealing with Fear of Cancer</td>
<td>Cancer Screening in Malaysia</td>
<td>Chairperson: Matin Mellor</td>
<td></td>
</tr>
<tr>
<td>0900 - 0930</td>
<td></td>
<td><strong>SYMPOSIUM 5A</strong></td>
<td>Abd Razak Ahmad</td>
<td>Ranjit Kaur</td>
<td>Nor Saleha Ibrahim Tamim</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0930 - 1010</td>
<td></td>
<td><strong>PLENARY 4</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1010 - 1040</td>
<td></td>
<td><strong>PLENARY 4</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1040 - 1150</td>
<td></td>
<td><strong>PLENARY 5</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1150 - 1220</td>
<td></td>
<td><strong>PLENARY 5</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1220 - 1230</td>
<td></td>
<td><strong>CLOSING CEREMONY</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1230 - 1430</td>
<td></td>
<td><strong>CLOSING CEREMONY</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1230 - 1330</td>
<td></td>
<td><strong>Annual General Meeting of the Academy of Medicine of Malaysia</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

**Tea / Booth Visit**

**PLENARY 4**
Chairperson: Letchuman Ramanathan
Equitable Access to Treatment via Value-Based Medicine
_Asrul Akmal Shafie_

**Joint MOS SSO Grand Round**
Chairperson: Ravindran Kanesvaran
Co-Chairperson: Tho Lye Mun

**PLENARY 5**
Chairperson: Muhammad Azrif Annuar
Key Advances in Cancer Treatment
_Fuad Ismail_

**Closing Ceremony**
Poster Winner, YIA, Quiz Winners

**Annual General Meeting of the Academy of Medicine of Malaysia**

**Lunch (for Non-Academy Members)**
THANK YOU

The Council of the Academy of Medicine of Malaysia and the Organising Committee of the
52nd Malaysia-Singapore Congress of Medicine
incorporating the
Annual Scientific Meeting 2018 of the College of Physicians, AMM
Annual Scientific Congress of the Malaysian Oncological Society (ASCOMOS) 2018
record their appreciation to the following for making the Congress a success:

Istana Perak
Ministry of Health Malaysia
Kuok Foundation Berhad

ACKNOWLEDGEMENTS

The Organising Committee expresses its grateful thanks to the following companies who have contributed in one way or another to the success of the
52nd Malaysia-Singapore Congress of Medicine
Annual Scientific Meeting 2018 of the College of Physicians, AMM
Annual Scientific Congress of the Malaysian Oncological Society (ASCOMOS) 2018

PLATINUM & GOLD SPONSOR
Novartis Corporation (Malaysia) Sdn Bhd

PLATINUM SPONSORS
A Menarini Singapore Pte Ltd
Merck Sharp & Dohme (Malaysia) Sdn Bhd

GOLD SPONSORS
Pfizer (Malaysia) Sdn Bhd
Eli Lilly (Malaysia) Sdn Bhd
Roche (Malaysia) Sdn Bhd

SPONSORS
Abex Medical System Sdn Bhd
Accord Healthcare Sdn Bhd
Aspen Medical Products Malaysia Sdn Bhd
AstraZeneca Sdn Bhd
Baxter Healthcare (Malaysia) Sdn Bhd
Bayer Co (Malaysia) Sdn Bhd
Boehringer Ingelheim (M) Sdn Bhd
CCM Pharmaceuticals Sdn Bhd
Celgene Sdn Bhd
Clinical Research Malaysia
Dr Reddy’s Laboratories Sdn Bhd
Eisai (Malaysia) Sdn Bhd
Fresenius Kabi Malaysia Sdn Bhd
Genomic Health, Inc
Merck Sdn Bhd
Mexys Sdn Bhd
Mundipharma Pharmaceuticals Sdn Bhd
Nestle Health Science
Oncode Scientific Sdn Bhd
Sanofi Aventis (Malaysia) Sdn Bhd
Zuellig Pharma
POSTER PRESENTATIONS

PP 01 RARE CUTANEOUS PRESENTATION OF AL AMYLOIDOSIS: CASE REPORT AND LITERATURE REVIEW
Fong Voon Ken
Hospital Pekan, Pahang, Malaysia

PP 02 SKULL BASE LESIONS AND ADJACENT BONY INVOLVEMENT IN NASOPHARYNGEAL CARCINOMA AND THE POTENTIAL USAGE OF BONE SCAN
Ahmad Zaid Zanial, Tejvinder Kaur Sodhi Paritam Singh, Siti Zarina Amir Hassan
Nuclear Medicine Department, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia

PP 03 CLINICALLY MALIGNANT MENINGIOMA WITH RECURRENCE AND ADJACENT BONY EROSION CAUSING POSITIVE TRIPLE-PHASE BONE SCINTIGRAPHY: FEATURES OF ACTIVE DISEASE PROCESS AT THE TUMOUR SITE
Ahmad Zaid Zanial, Shalini Brama Kumar, Siti Zarina Amir Hassan
Nuclear Medicine Department, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia

PP 04 NASOPHARYNGEAL CARCINOMA 5 YEARS SURVIVAL OUTCOME IN A PRIVATE TERTIARY CARE MEDICAL CENTRE
Catherine Lee May Ling
Subang Jaya Medical Centre, Selangor, Malaysia

PP 05 FINDINGS FROM A 4-YEAR PROSPECTIVE COHORT STUDY OF POST-TRAUMATIC STRESS DISORDER (PTSD) AMONG PATIENTS WITH CANCER
Caryn Chan Mei Hsien, Ng Chong Guan, Taib Nur Aishah, Wee Lei Hum, Edward Krupat, Fremonta Meyer
Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia

PP 06 KNOWLEDGE, ATTITUDE AND PRACTICE OF TEMPORARY CONTRACEPTIVE METHODS AMONG MARRIED WOMEN ATTENDING A TERTIARY CARE HOSPITAL IN CHENNAI
Nithyananthan Peramanathan
Saveetha Medical College & Hospital, Chennai, India

PP 07 BILATERAL HEMORRHAGIC PLEURAL EFFUSION: A RARE COMPLICATION FOLLOWING KEROSENE INGESTION
Nithyananthan Peramanathan
Saveetha Medical College & Hospital, Chennai, India

PP 08 REAL WORLD DATA ON BREAST CANCER SURVIVAL IN A MALAYSIAN CANCER CENTRE
Azura R Ahmad, A Z J Ho, K Y Liow, A B Manivannan, M I Wahid
Beacon International Specialist Hospital, Selangor, Malaysia

PP 09 CLINICAL DECISION MAKING SKILLS OF INTERNS - CHART STIMULATED RECALL AS A METHOD OF STRUCTURED TEACHING AND ASSESSMENT
Nithyananthan Peramanathan
Saveetha Medical College & Hospital, Chennai, India

PP 10 AN INTERESTING CASE OF MYASTHENIC CRISIS
Jagadeesan Mohanan
Saveetha Medical College & Hospital, Chennai, India

PP 11 A STUDY ABOUT KNOWLEDGE, ATTITUDE AND PRACTICE (KAP) REGARDING WORM INFESTATION AMONG THE CAREGIVERS OF CHILDREN AGED BETWEEN 5 - 12 YEARS
Jagadeesan Mohanan
Saveetha Medical College & Hospital, Chennai, India

PP 12 BROAD TRANSCRIPTOMIC PROFILES OF ASIAN BREAST CANCER
Pan Jia Wern
Cancer Research Malaysia, Selangor, Malaysia
POSTER PRESENTATIONS

PP 13  PREVALENCE OF PALB2 MUTATIONS IN AN UNSELECTED COHORT OF BREAST CANCER PATIENTS AND UNAFFECTED INDIVIDUALS FROM MALAYSIA
Patsy Ng, Soo Hwang Teo
Cancer Research Malaysia, Selangor, Malaysia

PP 14  AN INTERESTING CASE OF SCORPION STING INDUCED MYOCARDITIS
Banupriya Mohan
SRM Institute of Medical Sciences, Chennai, India

PP 15  A RARE CASE OF ADVANCED RENAL LEIOMYOSARCOMA
Jason Lai Shen Chang
Radiotherapy and Oncology Department, Hospital Umum Sarawak, Kuching, Sarawak, Malaysia

PP 16  TREATMENT OUTCOME FOR NASOPHARYNGEAL CARCINOMA (NPC) USING INTENSITY MODULATED RADIOTHERAPY (IMRT) IN MOUNT MIRIAM CANCER HOSPITAL (MMCH) FROM 2010-2014
Benjamin Oh Zheming
Cancer Research Malaysia, Selangor, Malaysia

PP 17  AN INTERESTING CASE OF JAUNDICE
Jagadeesan Mohanan
Saveetha Medical College & Hospital, Chennai, India

PP 18  IMPROVED CONFORMAL TECHNIQUE TO AVOID MARROW TOXICITY IN CHEMORADIATION OF CARCINOMA UTERINE CERVIX
Banupriya Mohan
SRM Institute of Medical Sciences, Chennai, India

PP 19  SHOULD WEAKLY POSITIVE HORMONE RECEPTOR BREAST CANCER BE TREATED AS HORMONE RECEPTOR NEGATIVE BREAST CANCER?
C Y Song1, C V Song2, M M Abdullah3, M M Yusof4, Y C Foo3, B K Yap5, Y S Ng6, Ivan Shew7, R Pathmanathan5, C H Yip5
1University of Galway, Galway, Ireland
2Cancer Research Malaysia, Selangor, Malaysia
3Ramsay Sime Darby Health Care, Selangor, Malaysia
4Parkcity Medical Centre, Kuala Lumpur, Malaysia

PP 20  ROBOTIC VERSUS CONVENTIONAL LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER: A SYSTEMATIC REVIEW WITH META-ANALYSIS
Azlan Tsia Kok Vui1, Ka Ting Ng2,3, Vanessa Yu Ling Chong1
1International Medical University, Kuala Lumpur, Malaysia
2University of Malaysia, Kuala Lumpur, Malaysia
3University of Edinburgh, United Kingdom

PP 21  INCIDENCE OF FEBRILE NEUTROPENIA WITH DOCETAXEL IN BREAST CANCER PATIENTS
Dai Wee Lee
Clinical Oncology Unit, University Malaya Medical Centre, Kuala Lumpur, Malaysia

PP 22  CHRONIC CEREBROSPINAL FLUID LEAKAGE: AN UNUSUAL COMPLICATION OF UNTREATED GIANT MACROPROLACTINOMA
Mohamad Nazrulhisham Mad Naser, Nor Azizah Aziz, Noor Khairiah A Karim
Hospital Pulau Pinang, Penang, Malaysia

PP 23  AN INCIDENTAL FINDING OF INTERNAL JUGULAR VEIN ECTASIA
Noor Khairiah A Karim, Noor Hasyima Mat Zain
Advanced Medical and Dental Institute, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia

PP 24  OCCUPATIONAL EXPOSURE TO CARCINOGENS AMONG MANUFACTURING WORKERS IN MALAYSIA
Jaseema Begum1, Marzuki Isahak1, Nirmala Bhoo-Pathy1, Azlan Darus2, Lin Fritschi1
1University of Malaya, Kuala Lumpur, Malaysia
2Social Security Malaysia, Kuala Lumpur, Malaysia
3Curtin University, Perth, Australia
More special moments for patients with mPC\(^a\), NSCLC\(^b\), and mBC\(^c\)

Abraxane is indicated for the treatment of

- Metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline-containing therapy is not indicated.
- Metastatic adenocarcinoma of the pancreas as first-line treatment of adult patients in combination with gemcitabine.
- Locally advanced or metastatic non-small cell lung cancer, as first-line treatment in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.

\(^a\) mPC = metastatic pancreatic cancer
\(^b\) NSCLC = non-small cell lung cancer
\(^c\) mBC = metastatic breast cancer

Reference: Abraxane Product Information.
HALAVEN® monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapy regimens for advanced disease (see CLINICAL STUDIES). Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments.

HALAVEN® is indicated as monotherapy for the treatment of locally advanced or metastatic HER2 negative breast cancer after failure of one chemotherapy regimen for advanced disease. Patients should have received an anthracycline and a taxane unless these treatments were not suitable.

HALAVEN® is indicated for the treatment of inoperable liposarcoma after progression following prior chemotherapy for advanced or metastatic disease in adults. Patients should have received two previous chemotherapy treatments, one of which should have included an anthracycline unless this treatment is unsuitable.

LENIMA® offers median 18.3 months in PFS and 64.8% in response rate. Time to first objective response at 2.0 months.

LENIMA® is indicated for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) Thyroid Carcinoma (DTC), Refractory to Radioactive Iodine (RAI).


For healthcare professional only.

Full prescribing information available on request.

Eisai (Malaysia) Sdn. Bhd. (18039-D) Lot 61, 6th Floor, Menara Lien Hoe, 8, Perisier Tropicana, 47410, Petaling Jaya, Selangor, Malaysia Tel:603-7803-9066 Fax:603-7803-0060
Introducing KRYXANA
A new CDK4/6 inhibitor for the treatment of HR+/HER2– locally advanced or metastatic breast cancer

Indicated for use in combination with any aromatase inhibitor

KRYXANA in combination with an aromatase inhibitor is indicated for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer as initial endocrine-based therapy.

KRYXANA® Basic Succinct Statement

Important note: Before prescribing, consult full prescribing information.
Presentation: Film-coated tablets (FCT) containing 200 mg of ribociclib.
Indications: Kryxana® is indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.

Dosage and administration:
Adults: The recommended dose of Kryxana is 600 mg (3 x 200 mg FCT) taken orally, once daily for 21 consecutive days followed by 7 days off treatment resulting in a complete cycle of 28 days.

Special populations: • Hepatic impairment: Mild: No dose adjustment is necessary. Moderate or severe: Dose adjustment is required, and the starting dose of 400 mg is recommended. • Pediatrics: Safety and efficacy have not been established.

Contraindications: • Patients with hypersensitivity to the active substance or to peanut, soya or any of the excipients.

Warnings and precautions: • Based on the severity of the neutropenia, Kryxana may require dose interruption, reduction, or discontinuation. • The ECG should be assessed prior to initiation of treatment. Treatment with Kryxana should be initiated only in patients with QTcF values <450 msec. The ECG should be repeated at approximately Day 14 of the first cycle and at the beginning of the second cycle, then as clinically indicated. Appropriate monitoring of serum electrolytes (including potassium, calcium, phosphorous, and magnesium) should be performed prior to initiation of treatment, at the beginning of the first 6 cycles, and then as clinically indicated. Any abnormality should be corrected before the start of Kryxana therapy. Based on the observed QT prolongation during treatment, Kryxana may require dose interruption, reduction, or discontinuation.

Adverse drug reactions:
Very common (≥10%): Urinary tract infection, neutropenia, leukopenia, anaemia, lymphopenia, decreased appetite, headache, insomnia, dyspnoea, back pain, nausea, diarrhoea, vomiting, constipation, stomatitis, abdominal pain, alopecia, rash, pruritus, fatigue, peripheral oedema, pyrexia, abnormal liver function tests, leukocyte count decreased, neutrophil count decreased, haemoglobin decreased, lymphocyte count decreased, platelet count decreased, alanine aminotransferase increased, aspartate aminotransferase increased, creatinine increased, phosphorous decreased, potassium decreased.

For Healthcare Professionals only
For full prescribing information, please contact:

Novartis Corporation (Malaysia) Sdn Bhd (109201-H)
Level 22, Tower B, Plaza 33, No.1, Jalan Kemajuan, Seksyen 13, 48200 Petaling Jaya, Selangor Darul Ehsan, Malaysia.
Tel: 03-7948 1886  Fax: 03-7948 1818  www.novartis.com